Kilitch Drugs (India) Limited (KILITCH) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Kilitch Drugs (India) Limited stock ₹147, price ₹239, that is 38.5% below the price, quality 30 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Kilitch Drugs (India) Limited
KILITCH · NSEFar too expensive (fair value 39% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range ₹63.33 – ₹260.70 · fair‑value band ₹110.01 – ₹183.35 · the ₹238.56 price screens above the ₹146.68 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 15, 2026.
Every Wednesday you see whether Kilitch Drugs (India) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally.
Show moreShow less
The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary products, iron supplements for anemia, Klavmox, and Onecef.
It also provides oral formulations, including tablets, capsules, dry syrup, and oral powder for antibiotic, anti-diabetic, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional products, including Celtine.
In addition, the company offers cosmetics, which include oil, lotion, liquid to cream, paste in skin, and personal and hair care products; herbal products for use in sore throat and prostate problems, as well as a supplement for diabetes, obesity, libido, and other conditions; ortho rehabilitation and implants; and medical devices comprising C-Seal, a skin adhesive to hold closely approximated skin edges without marks of sutures and incisions.
Further, it provides PH-7 which reduces acid content of the stomach; SRO kit for treating childhood diarrhea; 9-VIT for use in surgery, extensive burns, fractures, and other trauma; and HPURE for sore throat and cough. The company exports its products.
Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
Stock analysis
Kilitch Drugs (India) Limited (KILITCH) currently trades at ₹238.56, while our model-based Fair Value estimate is ₹146.68, 39% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹233.56 per share, and 2 of the 14 models we run sit above the ₹238.56 price.
Bear case: the Economic Profit group reads lowest at ₹51.59, and 12 of the 14 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹110.01 (bear) to ₹183.35 (bull), the price of ₹238.56 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Kilitch Drugs (India) Limited reported revenue of ₹2.4B in FY2026 versus ₹1.1B in FY2022, a compound +19.8%/yr. Reported net income was ₹302M in FY2026, compounding +42.3%/yr from FY2022.
Key figures
Market cap ₹8.1B (≈ $85.7M) Micro · P/E ratio 26.0 · P/S ratio 3.07 · EPS (TTM) ₹9.17 · Net margin 12.7% · Return on equity 12.4% · Return on assets (EBIT) 7.2% (5-year average) · Operating margin 4.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 92% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −39%, KILITCH screens richer than that median.
Fair Value models
All 14 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
KILITCH screens overvalued: fair value 39% below the price. Compare with Merck KGaA →
Compare Kilitch Drugs (India) Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Revenue growth by industry
- PEG ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs KILITCH |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.07 | ¥53.04 | +10% | vs KILITCH |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,880 | ₹1,983 | +5% | vs KILITCH |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs KILITCH |
| Merck KGaA MRK | €149.60 | €108.83 | −27% | vs KILITCH |
| Galderma Group GALD | CHF 191.40 | CHF 112.30 | −41% | vs KILITCH |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs KILITCH |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs KILITCH |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs KILITCH |
| Divi's Laboratories Limited DIVISLAB | ₹11,442 | ₹1,567 | −86% | vs KILITCH |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Kilitch Drugs (India) Limited (KILITCH) overvalued or undervalued?
What is the fair value of KILITCH?
What is the quality score of KILITCH?
What is the price target for Kilitch Drugs (India) Limited (KILITCH)?
What is the Kilitch Drugs (India) Limited stock forecast for 2026?
What is the revenue of Kilitch Drugs (India) Limited (KILITCH)?
What is the intrinsic value of Kilitch Drugs (India) Limited (KILITCH)?
Is Kilitch Drugs (India) Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of KILITCH?
How much is Kilitch Drugs (India) Limited worth?
What do the bullish and bearish scenarios say about KILITCH?
What is the P/E ratio of KILITCH?
How solid is the balance sheet of Kilitch Drugs (India) Limited (KILITCH)?
How far is KILITCH from its 52-week high?
Which stocks are comparable to Kilitch Drugs (India) Limited?
Is Kilitch Drugs (India) Limited stock attractive at the current price?
How is the fair value of KILITCH calculated?
Is it still worth investing in stocks now?
What is the share price of Kilitch Drugs (India) Limited (KILITCH)?
What should I pay attention to with Kilitch Drugs (India) Limited right now?
Key figures of Kilitch Drugs (India) Limited
How large is the market capitalisation of Kilitch Drugs (India) Limited (KILITCH)?
What is the P/S ratio of Kilitch Drugs (India) Limited (KILITCH)?
What are the earnings per share of Kilitch Drugs (India) Limited (KILITCH)?
What is the net margin of Kilitch Drugs (India) Limited (KILITCH)?
What is the return on equity of Kilitch Drugs (India) Limited (KILITCH)?
What is the EBIT return on assets of Kilitch Drugs (India) Limited (KILITCH)?
What is the operating margin of Kilitch Drugs (India) Limited (KILITCH)?
How fast is revenue growing at Kilitch Drugs (India) Limited (KILITCH)?
How fast are earnings growing at Kilitch Drugs (India) Limited (KILITCH)?
How much free cash flow does Kilitch Drugs (India) Limited (KILITCH) generate?
How much net debt does Kilitch Drugs (India) Limited (KILITCH) carry?
Watch Kilitch Drugs (India) Limited in the live analysis
One click puts Kilitch Drugs (India) Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.